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ABSTRACT 
Drug-inducible systems allow the modulation of duration and intensity of cytokine 
expression in liver immuno-based gene therapy protocols. However, the biological 
activity of the transgene may influence their function. We have analyzed the kinetics of 
IL-12 expression controlled by the doxycycline (Dox)- and the mifepristone (Mif)- 
dependent systems using two long-term expressing vectors directed to liver: a plasmid 
administered by hydrodynamic injection and a high capacity adenoviral vector. Daily 
administration of Dox or Mif was associated with a progressive loss of inducibility and 
a decrease of murine IL-12 production. This inhibition occurred at the transcriptional 
level and was probably caused by an IFN-γ-mediated down-modulation of liver-specific 
promoters that control the expression of transactivators in these systems. Genome-wide 
expression microarrays studies revealed a parallel down-regulation of liver-specific 
genes in mice over-expressing murine IL-12. However, a promoter naturally induced by 
IL-12 was also inhibited by this cytokine when placed on a plasmid vector. 
Interestingly, treatment with sodium butyrate, a class I/II histone deacetylase inhibitor 
was able to rescue liver-specific promoter activity solely in the vector. We conclude that 
biologically active IL-12 can transiently inhibit the function of drug-inducible systems 
in non-integrative DNA vectors by reducing promoter activity, probably through IFN-γ 
and protein deacetylation-dependant mechanisms.  
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INTRODUCTION 
 
The success of gene therapy depends on reaching adequate levels and duration of 
transgene expression in a target organ or tissue. When the therapeutic gene is toxic, this 
requirement needs to be coupled with an efficient gene regulatory system. However, the 
biological effects of the gene product in the organism may affect its own regulation in 
vivo through mechanisms that are difficult to predict in vitro. This is especially relevant 
in case of molecules with immunostimulating properties that have been successfully 
used in cancer gene therapy.  
Interleukin-12 (IL-12) a potent inducer of IFN-γ and has been shown to exert efficient 
antitumor effects against liver cancer. A strategy based on the intratumor (it) injection 
of an IL-12-expressing adenoviral vector (Ad-CMVmIL12) resulted in low toxicity, 
tumor reduction and prolonged survival in different animal models of metastatic and 
primary liver cancer (reviewed in 1). However, a limited and transient antitumor effect 
was evidenced with a similar approach using Ad-CMVhIL-12 vector in a Phase I 
clinical trial, probably due to low levels and short-term expression of the transgene 2,3. 
This prompted the development of new vectors and a strategy based on the long-term 
expression of IL-12 in the liver. In order to avoid toxicity of the cytokine we placed the 
two IL-12 chains under the control of the doxycycline (Dox) or the mifepristone (Mif)-
inducible systems 4,5 . This allows modulation of IL-12 expression in a dose and time-
dependent manner upon administration of the inducer drug (Dox or Mif), as reported for 
hGH and IFN-α in a similar setting 6,7. Here we study the influence of the biological 
effect of IL-12 on the in vivo function of these systems. In our study the production of 
IL-12 is restricted to the liver by placing transactivators (TA) under the control of 
tissue-specific promoters, and also by virtue of the vectors and delivery methods used. 
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In the case of the Dox-inducible system, the plasmid pTonT(L2)-IL12 was administered 
by hydrodynamic injection in mice 4, whereas the Mif-inducible system was delivered 
by intravenous or intrahepatic injection on a high-capacity adenoviral vector (GL-
Ad/RU-IL-12) 5. In each case, two sets of vectors were constructed to express either 
human IL-12 (hIL-12) or murine IL-12 (mIL-12). In mice, hIL-12 is not biologically 
active and it was used as a reporter gene whose production can be easily quantified in 
the serum of animals. We describe here the kinetics of mIL-12 expression induced from 
the pTonT(L2)-mIL12 plasmid and the viral vector GL-Ad/RUmIL-12 in the liver of 
immunocompetent mice. The results evidence a drastic, although reversible silencing of 
mIL-12 expression following continuous transgene induction. In contrast, the 
expression of hIL-12 was more stable using these same systems, as reported previously 
4,5. We have also defined the effect of mIL-12 on endogenous liver-specific gene 
expression and the participation of IFN-γ at least in initial stages of transgene inhibition 
on plasmid- and adenoviral-based vectors. Finally, we describe that the histone 
deacetylase inhibitor (HDACi) sodium butyrate (NaB) is able to alleviate transgene 
silencing in vivo.  
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RESULTS:  
 
1. Kinetics of IL-12 production using drug-dependant gene regulatory systems 
in mice.  
In order to study the influence of transgene expression on the function of inducible 
systems in vivo, we have used the immunostimulatory cytokine mIL-12 in the context of 
a Tet-on system (plasmid pTonL2(T)mIL12) or a Mif-inducible system (adenoviral 
vector Ad-GL/RUmIL-12). As a control, we used identical vectors expressing hIL-12, 
which is not biologically active in mice (pTonL2(T)-hIL12 and Ad-GL/RUhIL-12). 
Schematic representations of the plasmids and the adenoviral vector genomes are shown 
in figure 1A and 1B, respectively. The plasmid pTonL2(T)-hIL12 was administered to 
C57BL/6 mice by hydrodynamic (HD) injection, and hIL-12 induction was carried out 
by administration of Dox for 8 consecutive days. The concentration of hIL-12 in the 
serum of animals was measured at different time points by ELISA. In the absence of 
Dox, no hIL-12 was detected (data not shown). As expected, the continuous induction 
stimulated sustained levels of hIL-12, with only a moderate reduction at day 8 versus 
day 1 (Fig. 1C). In contrast, when the same procedure was carried out with the 
pTonL2(T)mIL12 plasmid in a 10 days induction protocol, a progressive reduction of 
mIL-12 was observed starting at day 3, with more than 100 fold decrease at days 8 and 
10 (Fig. 1E). Interestingly, when the same induction protocol was repeated after a 
resting period of 3 weeks, inducibility was restored (Fig. 1E, dark columns) and 
expression of mIL-12 followed the same pattern of progressive decline observed in the 
first round. Apart form a moderate reduction in the mIL-12 levels, the kinetics of both 
rounds of induction were identical. Similar experiments were performed with the viral 
vector carrying the Mif-inducible system. Ad-GL/RUhIL-12 or Ad-GL/RUmIL-12 were 
administered intravenously (i.v) by tail vein injection and IL-12 induction started 2 
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weeks later by daily intraperitoneal (i.p) injections of Mif. Serum IL-12 was measured 
10 h after drug administration. As shown in figure 1D, the inducibility was maintained 
in mice inoculated with Ad-GL/RUhIL-12, as previously reported 5. However, as 
observed with the plasmid vector, a progressive silencing of mIL-12 expression 
occurred (Fig. 1F). Again, a short period without induction (in this case of 10 days) was 
sufficient to recover the function of the system almost completely (Fig. 1F, dark 
columns). These results indicate that the biological activity of a transgene product such 
as IL-12, can inhibit the function of a drug-inducible system. This effect seems to be 
independent on the regulatory system and the type of vector used. The recovery of 
inducibility after a resting period argues against the loss of transgene as the explanation 
for this phenomenon. In fact, measurement of vector DNA by real time RT-PCR after 8 
daily inductions did not reveal a significant reduction compared with the first day of 
induction (data not shown). 
 
2. Inhibition of IL-12 expression is associated with transactivator down-
regulation  
In order to study the mechanism of mIL-12 reduction, we analyzed if the amount of 
protein detected in serum was associated with a parallel decrease of mRNA. To this end, 
we sacrificed animals that had been treated with pTonL2(T)mIL12 or Ad-GL/RUmIL-
12 at the beginning or the end of the induction protocol, and quantified the amount of 
mIL-12 mRNA in the liver. As shown in figure 2A and B, continuous induction caused 
a drastic (40-fold) reduction of mIL-12 mRNA independently of the vector used. We 
next explored whether the system was inhibited at the level of TA production, since 
transcription of mIL-12 is controlled by inducible promoters that respond to rtTA2S-M2 
or GLp65 in the Dox and Mif-dependant systems respectively, and there is a direct 
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correlation between TA levels and transgene induction 4. To this end we quantified 
rtTA2S-M2 and GLp65 mRNAs in the same liver samples used above. We observed 20 
fold decrease expression of both TAs, which was consistent with the reduction of mIL-
12 levels (Fig. 2C and D). In contrast, a similar amount of TAs and hIL-12 mRNAs was 
detected throughout all the induction protocol (data not shown). Interestingly, at day 1 
rtTA2S-M2 expression was enhanced about 2 times with Dox compared to untreated 
animals (Fig. 2C). This effect was seen when Dox was given either i.p or in drinking 
water and also when using hIL-12 or luciferase reporter genes under the control of the 
Dox-inducible system (data not shown). A similar behavior was observed for Mif-
treated animals (Fig. 2D). These observations suggest that although Dox and Mif can 
induce TA expression by themselves, this induction cannot alleviate the repression 
effect of mIL-12 on gene transcription after several days of drug administration. 
Together, our data indicate that mIL-12 induces reduction of rtTA2S-M2 and GLp65 
mRNA levels, and therefore a negative feedback is established causing a decrease of 
mIL-12 expression, unrelated to loss of vector DNA. This suggests that inhibition of TA 
expression could be the consequence of EalbPα1AT and TTR promoter silencing, since 
rtTA2S-M2 and GLp65 are driven by these liver-specific promoters in the Dox- and 
Mif-dependant systems, respectively (Fig. 1A and B). 
 
3. Effect of mIL-12 on liver-specific gene expression.  
In order to obtain a general perspective about the influence of IL-12 on liver-specific 
promoters, we performed gene expression microarray analysis to identify genes that are 
differentially expressed in response to this cytokine. To this end, mice were injected 
with the pTonL2(T)-mIL12 or control plasmid EalbPα1AT-rtTA2 4, in which the TA is 
expressed but no IL-12 cassette is present. Both groups were treated with Dox for 3 
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consecutive days, and then liver samples were collected for RNA extraction and 
analysis. A total of 2030 genes-probesets (with False Discovery Rate, FDR=0.05) were 
found altered when mIL-12 was induced. Among them, a number of IFN-γ responsive 
genes such as Icsbp1, Ifi47, Ifi203, Iigp1, Irf1, Stat1, and Ifn-γ itself were up-regulated 
(Fig. 3A). Since activation of IFN-γ is a hallmark of IL-12 function in vivo 8, this 
observation demonstrates the biological activity of the transgene and the functional 
relevance of the results found using the genome-wide expression microarrays. We next 
focused on a set of 101 liver-specific genes, selected based on a 200 fold higher 
expression in murine liver compared with other tissues according to the transcriptomic 
profiles in Gene Expression Atlas (http://symatlas.gnf.org/SymAtlas/) 9. We searched 
for these liver-specific genes in the microarrays and found a set of 94 gene-probesets, 
which were used to perform a hierarchical cluster analysis. The resulting gene 
expression profiles along the 6 sample microarrays are presented as a heatmap (Fig.3B). 
It shows a clear differential expression between the samples in which mIL12 was 
induced (TAdIL 1, 2 and 3) and the ones that remained in the basal state (TAd 1, 2 and 
3). These sets of genes present a mean difference in expression of 0.35 (in log2) 
between the two states. Among the genes repressed in the presence of mIL-12 we found 
albumin (Alb1), α-1antitrypsin (also called Serpina1a) and transthyretin (Ttr) (Fig. 3B). 
This is important because analogous promoters and/or enhancers of these genes where 
included in the Dox- and Mif- dependant gene inducible system to direct TA expression 
(Fig. 1A and B). To confirm these data we performed an independent experiment in 
which the plasmids pTonL2(T)-mIL12 or pTonL2(T)-hIL12 were administered by 
hydrodynamic injection and induction was carried out for 8 days. At this time, mRNA 
corresponding to these genes was quantified from the liver of mice by real time RT-
PCR. No differences in albumin, α-1antitrypsin and transthyretin mRNA levels were 
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found in animals expressing hIL-12 compared to untreated controls (data not shown). In 
contrast, mIL-12 caused a 3 to 8 fold reduction in the expression of these liver-specific 
genes (Fig. 3C-E), The results indicate that the biologically active mIL-12 causes a 
significant repression of endogenous liver-specific promoters that are relevant for the 
function of our inducible systems. On the other hand, a number of genes like hemopexin 
(Hpxn) were up-regulated in response to mIL-12 expression, as revealed in the 
microarray analysis (Fig 3B), and confirmed by real time RT-PCR (Fig. 3F). 
 
4. An IL-12 inducible promoter does not alleviate transgene silencing  
In order to analyze the direct influence of mIL-12 on the promoters used to control TA 
expression, we used a plasmid carrying the hAAT gene driven by the EalbPα1AT 
promoter (EalbPα1AT-hAAT) 10. Human AAT is a good reporter protein in Balb/c mice 
and can be easily monitored in serum by ELISA, unlike intracellular TA proteins. 
EalbPα1AT-hAAT plasmid was co-administered with either pTonL2(T)mIL12 or 
pTonL2(T)hIL12 by hydrodynamic injection. As expected, activation of mIL-12 
expression by Dox caused a marked decrease in hAAT levels after 8 days of induction, 
whereas no effect was observed with hIL12 (Fig. 4A). The same result was observed 
using a plasmid containing the TTR promoter driving the expression of hAAT (data not 
shown). This result initially suggested that mIL-12 exerts the same influence on 
endogenous promoters as well as those located in extrachromosomal plasmids. If this 
were a general feature, we would expect that the promoters of genes up-regulated by 
mIL-12, such as hemopexin, could be used to drive the expression of TAs and avoid 
mIL-12-mediated down-regulation in the inducible system. In addition, the hemopexin 
promoter seems a good candidate because it was shown to respond to IL-6-mediated 
inflammation signals 11 and to drive stable transgene expression if combined with an EII 
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HBV liver-specific enhancer 10. In order to test this strategy, we repeated the experiment 
described in figure 4A using the EIIPHpx-hAAT plasmid instead of EalbPα1AT-hAAT. 
Surprisingly, we found down-regulation of hAAT expression in response to mIL-12 
induction (Fig. 4B), which could indicate dissociation between the effect on the 
endogenous and the extrachromosomal vector-derived promoter. 
 
5. Involvement of IFN-γ in the inhibitory effect of IL-12 on gene expression. 
IL-12 stimulates the production of IFN-γ  in different cell types, and this mediates many 
of the biological effects of this cytokine. To define whether the inhibition of liver-
specific gene regulatory systems was a direct effect of IL-12 on transduced hepatocytes, 
or if it was mediated by IFN-γ, we analyzed the presence of IL-12 and IFN-γ receptors 
in murine hepatocytes. The expression of IL-12 receptor β1 and β2 chains and IFN-γ 
receptor α and β chains were quantified in total mRNA samples isolated from primary 
murine hepatocytes, whole liver samples and from the well-differentiated murine 
hepatocellular carcinoma cell line Hepa1-6. Both receptor subunits need to be present in 
the same cell for efficient signal transduction 12. We found that only the β2 chain of IL-
12 receptor is expressed in hepatocytes and in Hepa1-6 cells (Fig. 5 A and B), 
indicating that these cells are not able to transmit IL-12-mediated signals. The detection 
of both chains in whole liver samples (Fig. 5A and B) may be the due to the presence of 
non-parenchymal cells such as T lymphocytes and NK cells. On the other hand, as 
previously described for most somatic cells 13, a functional IFN-γ receptor is present 
also in liver, hepatocytes and Hepa1-6 cells (Fig. 5 C and D). Since IL-12 can activate T 
and NK cells to produce IFN-γ, and this cytokine is abundantly secreted in IL-12-
stimulated organisms 14, these data indicate that the effect of IL-12 on transgene 
silencing may be mediated by IFN-γ signaling in hepatocytes. In order to demonstrate 
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this hypothesis we compared the kinetics of mIL12 expression in wild type (wt) and in 
IFN-γ receptor α ko mice (IFN-γ R-/-) that received the Ad-GL/RUmIL-12 vector and 
were subjected to 7 daily inductions of mIL-12 with Mif. In contrast to wt mice, a 
sustained expression of mIL-12 was observed in the IFN-γ-R ko mice during all the 
induction period despite the high levels of IFN-γ detected in both types of animals (Fig. 
6A and B). This indicates an important role of IFN-γ signaling in the down-regulation of 
liver-specific drug-inducible systems. In order to investigate if this effect could be 
attributed to the immunostimulatory functions of IFN-γ, we studied if silencing takes 
place in severely immunosuppressed animals like nod/SCID mice. As shown in figure 
6, a parallel decline in mIL-12 expression in wt and nod/SCID mice was observed, 
indicating that transgene silencing does not require an efficient immune system but only 
the ability of lymphoid cells to produce IFN-γ in response to IL-12, and the expression 
of IFN-γ receptors. 
 
6. Sodium butyrate can rescue mIL-12 silencing without affecting IFN-γ 
signaling  
Histone deacetylase inhibitors (HDACi) induce euchromatin conformation and can 
revert gene silencing in a variety of circumstances 15. It has been reported that HDACi 
can increase the expression of endogenous 16 as well as extrachromosomal transgenes in 
vitro and in vivo 17. Therefore, we studied if Sodium Butyrate (NaB), a commonly used 
HDACi, was able to restore mIL-12 expression when induced from the pTon(L2)-
mIL12 vector. The plasmid was administered to mice as previously described, and 
induction of mIL-12 with Dox was carried out for 8 days in the presence or absence of 
NaB treatment at 1.25 or 2 g/kg. As shown in figure 7A, NaB partially avoided the 
reduction of mIL-12 production in a dose-dependent manner. Animals treated with 2 
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g/kg NaB achieved 10 times higher cytokine levels as compared to untreated mice at the 
end of the induction period. This dose of NaB has been described to be sufficient to 
recover the acetylation status of histones in mice, and is not associated with toxic effects 
18,19. Following NaB treatment, the mIL-12 concentration in serum correlated with an 
increase in rtTA2S-M2 and mIL12 mRNAs in the liver of mice measured at day 8 (Fig. 
7B). In order to determine whether NaB was protecting not only the promoters present 
in vector DNA, but also the corresponding endogenous liver-specific promoters, we 
measured expression of albumin, α-1 antitrypsin and transthyretin in the same liver 
samples. We did not see any difference in the expression of these three genes in treated 
and untreated animals, indicating that NaB is not able to prevent mIL-12-mediated 
endogenous gene down-regulation in mice (Fig. 7B). These data suggest that the 
mechanisms responsible for vector promoter silencing may be different from the ones 
affecting the cellular genome. Since IFN-γ can induce transgene down-regulation 20 
(Fig. 6A), and some HDACi suppress synthesis of various cytokines, including IFN-γ 21 
22, we investigated whether the protective role of NaB was due to a blockade of IFN-γ 
signaling pathways in our assay conditions. To this end, we measured the expression of 
the downstream genes Stat1 and Ifit2 in the liver of mice that received the pTon(L2)-
mIL12 plasmid and were given Dox for 8 days in the presence or absence of NaB. As a 
negative control for IFN-γ pathway activation we included IFN-γ-R ko mice over-
expressing murine IL-12. As expected, the expression of Stat1 and Ifit2 was increased 
in response to mIL-12 in wt but not in IFN-γ-R ko mice (Fig. 7C). NaB caused no 
variation in either the basal or the mIL-12-induced expression of Stat1 and Ifit2 (Fig. 
7C), and similar amount of IFN-γ was detected in the serum of NaB-treated and 
untreated mice (data not shown). These data indicate the lack of an obvious interference 
of NaB on IFN-γ production and signaling.  
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DISCUSSION 
The ability to exogenously modulate the intensity and duration of transgene expression 
is essential when placing transgenes with toxic potential in long-expressing vectors. The 
use of drug-inducible systems would allow the design of tailored protocols adapted to 
the disease and the status of the patient. In the case of IL-12 these features are critical 
and may determine the safety and efficacy of the treatment because this cytokine causes 
severe toxicity at high doses. In this study we have characterized the in vivo 
performance of drug-inducible systems based on hepato-specific promoters for the 
regulation of IL-12 expression within the liver. We provide evidence that the biological 
activity of IL-12 causes a gradual inhibition of these systems. Their ability to induce 
transgene expression is reduced after 3 days of drug administration, and it virtually 
disappears after an 8-10 days induction period. This phenomenon occurs with both 
regulatory systems tested in the present work: the Tet-on and Mifepristone-dependant 
systems, and it is not related to the vector (naked DNA or high-capacity adenoviral 
vector) or delivery method used (hydrodynamics-based injection or intravenous and 
intrahepatic liver transduction). It also seems to be independent on the strain of mice 
analyzed, because we observed the same effect on C57BL/6J and Balb/c (Fig. 1), as 
well as in 129S2/SvHsd mice (manuscript in preparation). Interestingly, the silencing of 
gene expression is not an intrinsic limitation of these regulatory systems, since 
continuous activation of gene expression can be maintained with other transgenes, like 
human IL-12 and luciferase, that do not elicit the biological effects of murine IL-12 in 
mice 4-6. This indicates that potential problems regarding the pharmacokinetics of 
inducer drugs (Dox and Mif) can be discarded.  
 14
Due to the complex functions of IL-12 in vivo, a number of different mechanisms may 
account for the rapid silencing of gene expression observed. We have ruled out the 
possibility that it is due to the elimination of transduced cells, since no specific decrease 
of transgene content was observed in the liver of induced mice (data not shown). This is 
in agreement with the ability of the systems to recover maximum inducibility after a 
resting (drug-free) period of at least 5 days (Fig.1 and our unpublished data). The 
blockade of IL-12 production was at the level of transcription, because a parallel 
reduction of its mRNA was observed. The mechanism involves a down-regulation of 
both Dox- and Mif- associated TA gene expression (rtTA2s-M2 and GLp65 
respectively), suggesting an inhibition of the liver-specific chimeric promoters that were 
used to control the expression of these TA in our systems 4,5. The promoters were 
constructed by combining regulatory sequences from the mouse albumin, human α-1 
antitrypsin and mouse transthyretin genes, which allow sustainable and high levels of 
reporter gene expression in mice 6,10. Interestingly, gene expression microarray analysis 
(together with real time RT-PCR validations) indicated that endogenous expression of 
albumin, α-1 antitrypsin and transthyretin was inhibited in animals over-expressing IL-
12, which is consistent with changes observed in acute-phase response 23,24. Therefore it 
was possible that these elements were also inhibited in the expression cassettes 
introduced in our vectors. However, although the endogenous expression of hemopexin 
was increased in response to IL-12, the hemopexin promoter was equally down-
regulated by IL-12 when placed on a plasmid vector to control hAAT reporter gene 
expression. This indicates that IL-12 may influence differently the transcriptional 
activity of regulatory sequences depending on their localization: chromosomic or 
extrachromosomic. Therefore, we believe that the performance of tissue-specific 
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promoters on gene therapy vectors is difficult to predict based just on endogenous gene 
expression profiles.  
The choice of vectors and the design of expression cassettes used in the present study 
ensure the synthesis of IL-12 in hepatocytes, but the cytokine is rapidly secreted to the 
circulation, where it can reach specific receptors present in the surface of target cells 
such as T lymphocytes and NK cells. When activated, these cells will secrete IFN-γ  8. 
Based on our observation that murine hepatocytes do not express functional receptors 
for IL-12, the silencing of gene expression must be mediated by an indirect mechanism, 
most probably related to the activation of the IFN-γ pathway. This concept is supported 
by our finding that in knockout mice for the IFN-γ receptor the system does not suffer 
the loss of inducibility observed in wt animals. IFN-γ plays a pivotal role in the 
development of adaptive immune responses and antitumor activity mediated by IL-12; 
however it could diminish gene therapy efficacy through transgene silencing. This is in 
agreement with previous observations from other groups using plasmid, adenoviral and 
retroviral vectors in vitro and in vivo 20,25,26. In any case, it is worthwhile to stress that 
this is a reversible transcriptional inhibition and gene expression can be recovered after 
a cytokine-free resting-period. In addition, we describe here that silencing takes place in 
animals with severely impaired immune system such as nod/SCID mice. Together, these 
data indicate that transcriptional inhibition mediated by IFN-γ in hepatocytes is 
responsible for this phenomenon, independently of the immunological effects of this 
molecule. 
Gene expression can be regulated through chromatin remodeling mediated by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). This is a dynamic 
process that can be affected by structurally diverse HDACi, including NaB 15,27. Here we 
describe that NaB treatment alleviates transgene silencing in vivo in our assay conditions. This 
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is consistent with the recent observation of episomal vector chromatinization in the liver 
of transfected mice 28. Enhanced expression of transgenes upon treatment with NaB was 
previously observed by other groups using adenoviral vectors 29 and naked DNA 17,30. 
However the mechanism responsible for this phenomenon is difficult to access since 
HDACi affect a number of cellular proteins beside histones 15. The ability of IFN-γ to 
decrease histone acetylation through activation of HDACs or inhibition of HATs has 
been described in different systems 31,32 and is believed to be relevant for its biological 
functions 33,34. We observed protection from transgene silencing by NaB without major 
disruption of IFN-γ pathways such as those leading to Stat1 and Ifit2 induction. Thus, it 
could re-activate transgene expression by unraveling chromatin at relevant vector 
promoter sequences, by activating transcription factors or by any of the numerous 
alternative mechanisms defined for HDACi 15,27. Interestingly, the effect of NaB was 
predominant on extrachromosomal DNA, since no re-activation of endogenous liver-
specific promoters was observed. Although the mechanism is not clear at this moment, 
the development of methods to counteract IL-12 transgene silencing is relevant because 
maintenance of sustained levels of this cytokine for a defined period of time may be 
necessary to achieve an optimal therapeutic response. The use of HDACi as adjuvants in 
the induction regime would be possible in humans, since several of these agents are 
being investigated as anti-cancer agents in clinical trials 27. Moreover, some HDACi 
have shown to greatly stimulate standard chemotherapy and gene therapy strategies 
against liver cancer in experimental models 35,36. 
In summary, we describe here that Dox- and Mif- dependant regulatory systems suffer a 
rapid loss of inducibility when they express biologically active IL-12. The inhibition is 
transient, is mediated by IFN-γ and is partially blocked by HDACi. These observations 
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have relevance for the design of gene therapy strategies involving controlled expression 
of immunostimulatory cytokines for the treatment of cancer and other diseases.  
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MATERIALS AND METHODS 
 
Animal manipulation. 5-6 week-old female C57BL/6J and BALB/c mice were 
purchased from Harlan Laboratories (Barcelona, Spain). Nod/SCID mice (NOD.CB17-
Prkdc scid/J) were obtained from Jackson Laboratory. Interferon-γ receptor-deficient 
mice (IFN-γ R −/−) were provided by Dr. Gonzalez-Aseguinolaza 37. Animals were 
maintained under standard conditions and all procedures were approved by the 
institutional ethical comitee. Each plasmid DNA (50 μg) resuspended in 2 ml of saline 
(NaCl 0.9%) was injected into mice using the hydrodynamics-based procedure 38. The 
viral vector was administered by tail vein injection diluted in 200 μl of saline or by 
intrahepatic (i.h) injection in 50 μl to increase transduction efficacy. Direct hepatic 
injection was performed following laparotomy, as described 39. In the case of the Tet-on 
system, inductions started one week after plasmid injection. Doxycycline (Sigma) was 
given in drinking water (2 mg/ml with 5% sucrose) or by i.p injection (50 μg/g). In the 
case of the Mif-inducible system, Mifepristone (Sigma) was administered by i.p 
injection starting two weeks after the vector administration at a dose of 250μg/kg 
dissolved in 60 μl of sesame oil. NaB (Sigma) was daily administered i.p at 1.25 or 2 
g/kg after the second day of induction. Blood samples were obtained by retro-orbital 
bleeding under inhalatory anesthesia (isoflurane, Forane® Abbott Laboratories). When 
Dox or Mif were administered i.p, blood was collected after 10 hours. When Dox was 
given orally blood was taken in the morning. Serum was recovered by double 
centrifugation at 10,000 rpm for 5 min and stored at −20°C until protein measurement. 
 
Vectors. The pTonL2(T)-hIL12 and pTonL2(T)-mIL12 plasmids were generated as 
described 4. In both constructs the EalbPα1AT promoter directs the expression of the 
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Dox-responsive transactivator rtTA2S-M2. GL-Ad/RU-mIL12 adenoviral vector carry 
the Mif-responsive transactivator (GLp65) under the control of the liver-specific 
transthyretin (TTR) promoter 6 and was generated as reported 5. The p35 and p40 of 
IL12 are linked by IRES. Plasmids EalbPα1AT-hAAT and EIIPHpx-hAAT express the 
human α1-antitrypsin (AAT) gene under the control of liver-specific promoters 
described previously 10. Plasmid DNA was purified from bacteria using Endofree® 
Plasmid Maxi Kit (Qiagen, Santa Clara, CA, USA) and stored in Tris–EDTA (TE 10:1) 
buffer solution at −20°C. HC-Ad vector stocks were prepared and stored as described 
earlier 5. 
 
Hepatocyte isolation. The liver of 8 week-old female C57BL/6J mice were perfused 
with collagenase solution (Sigma) and hepatocytes were isolated as described 40. Cells 
were stored at –80ºC before analysis. 
 
Determination of IL-12, IFN-γ and AAT levels. Serum concentration of IL-12 and 
IFN-γ were determined by OptE1A human IL-12 (p70), OptE1A mouse IL-12 (p70) and 
mouse IFN-γ ELISA kits (BD Bioscience PharMingen, San Diego, CA). Serum levels 
of AAT were measured by ELISA as described previously 10. 
 
RNA isolation, DNA Extraction and RT-PCR. After sacrifice, liver samples were 
harvested, rapidly frozen in liquid nitrogen and stored at –80ºC. Total RNA was 
extracted with TRIzol®Reagent (Invitrogen) from a portion of liver (10mg) 
homogenized with an Ultraturrax Driver T.25 (Janke & Kunkel, Ika-Labortechnik, 
Germany), following the manufacturer’s protocol. The RNA was stored at -80°C before 
further processing. Genomic DNA was eliminated from the samples by DNase I 
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(Invitrogen) treatment using 1μ/μg RNA. Total cDNA was generated using 2μg RNA in 
50 µl mix containing 0,8 mM dNTP Mix, 5,3 mM p(dN)6 random primers (Roche), 
4mM dTT (Invitrogen), 48 units of RNase inhibitor (Invitrogen), 240 units of M-MLV 
reverse transcriptase (Invitrogen) and 10 µl of buffer provided by the supplier. The tubes 
were incubated at 37°C for 1 hour and 95°C for 1 min.  
 
Quantitative PCR. cDNA, was quantified using the iQTM SYBR® green Supermix in a 
iQTM5 system from Bio-Rad. We designed all primers (Table 1) to distinguish between 
genomic and cDNA amplification, except for Ifit2 and the plasmid amplicons. In these 
cases, absence of genomic DNA contamination after DNAse treatment was 
demonstrated by qPCR. The PCR amplification was performed under the following 
conditions: one cycle of 95ºC for 3 min; 40 cycles of 95ºC for 15 s, 58-62ºC for 30 s 
(annealing), 72ºC for 30 s, 79-82ºC (detection) for 10 s; followed by a final extension of 
72ºC for 4 min. Immediately following the PCR, a melting curve was undertaken by 
raising the incubation temperature from 55 to 95 °C to confirm amplification specificity. 
For the same purpose, we also performed electrophoresis of the final PCR product. 
Annealing temperature is 60ºC for all the set of oligos except for AAT (Serpina1), 
which was performed at 58,5ºC, Stat1 at 62ºC and Il12rb2 at 58oC. Detection 
temperature was 79ºC for IRES, GLp65, Ifit2 and albumin DNA, and 82ºC for all the 
rest. Samples were run in duplicate and mRNA levels were normalized using 
glyceraldehyde-3-phosphate dehydrogenase (gapdh) as an internal control. The amount 
of each transcript was indicated by the formula: 2Ct(gapdh)-Ct(gene), being Ct the point at 
which the fluorescence rises appreciably above background.  
 
Microarray data analysis: normalization, signal calculation, significant differential 
expression and sample/gene profiles clustering. We used GeneChip® Mouse Genome 
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430A 2.0 Array (Affymetrix®) representing approx. 14,000 well-characterized mouse 
genes. Microarray data analysis was performed using the following strategy and 
methods. RMA algorithm was used for background correction, intra- and inter-
microarray normalization and expression-signal calculation 41,42. Once the absolute 
expression signal for each gene (i.e. the signal value for each gene probeset) was 
calculated for the whole microarray set, SAM algorithm 43 was applied to calculate 
significant differential expression and find the gene probesets that changed in each type 
of samples. The method uses permutations to provide robust statistical inference of the 
most significant probesets and provides p-values adjusted to multiple testing using FDR 
(False Discovery Rate) 44. The cut-off of adjusted p-values applied to select significant 
genes was < 0.05. After the identification of the differentially expressed gene probesets, 
the corresponding matrix of expression values for the microarray samples studied was 
analyzed using the “hclust” clustering algorithm 45. This algorithm performs 
agglomerative hierarchical cluster analysis with complete linkage to find similarity 
between gene probesets based on their similar gene expression profiles along the 
analyzed microarray samples. We applied these methods using R and Bioconductor as 
main computational and bioinformatic tools (www.bioconductor.org). R is a 
programming language and software environment for statistical computing (www.r-
project.org). The normalized expression signals calculated for the genes in Figure 3A 
correspond to the average of ratios of log2 expression signals. The ratios were obtained 
dividing the log2 signal of each gene in each sample by its median expression value 
along the 6 mice samples. In this way the controls are close to 1 (that indicates no-
change) and the changes in log2 scale are comparable for the different genes. 
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Statistical analysis. Data were analyzed by Mann-Whitney nonparametric tests. We 
used nonparametric statistics because sample size was less than 10. 
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FIGURE LEGENDS 
 
Fig.1. Schematic representation of vectors and kinetics of IL-12 expression. (A) 
pTonL2(T)-IL12: plasmid containing the Tet-on system in which the rtTA2s-M2 
transactivator is controlled by the EalbPα1AT promoter (mouse albumin enhancer fused 
to human α1-antitrypsin promoter). (B) GL-Ad/RU-IL-12: adenoviral vector carrying 
the Mif-inducible system in which the GLp65 transactivator is controlled by the 
transthyretin promoter (TTR). tetO7: rtTA2s-M2 DNA binding site. Palb: minimum 
albumin promoter; ITR: inverted terminal repeat; Ψ: adenoviral packaging signal; 
HPRT and C346: stuffer DNA derived from human hypoxanthine phosphoribosyl 
transferase locus and human cosmid C346, respectively; GAL4BS: GLp65 DNA 
binding site; E1b-TATA: adenoviral E1b minimal promoter. (C) pTonL2(T)-hIL12 
(50µg) was administered to C57BL/6J mice (n=5) by Hydrodynamics injection 
followed by 8 days-induction period with Dox. (D) GL-Ad/RU-hIL-12 (3x109 IU) was 
administered to C57BL/6J mice (n=5) by i.v. injection and Mif was administrated for 10 
days i.p. (E) pTonL2(T)-mIL12 (50µg) was injected into BALB/c mice (n=5), and Dox 
was administrated in two rounds separated by a 3 week resting period. (F) GL-Ad/RU-
mIL12 (2,5x108 IU) was inoculated to C57BL/6J mice (n=4) followed by two rounds of 
Mif administration separated by a 10 days resting period. IL-12 was measured on serum 
samples at the indicated time points. 
 
Fig.2. Quantification of mRNA levels. Murine IL-12 mRNAs (A, B) and the 
transactivators rtTA2S-M2 (C) and GLp65 (D) were analyzed by real time RT-PCR in 
liver samples extracted from C57BL/6J mice treated with the indicated vectors. (A, C) 
pTonL2(T)-mIL12 plasmid was injected by the hydrodynamics procedure (n=20) and 
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five animals per group were sacrificed 16 hours after given or not Dox in drinking water 
(day 1) and at day 8. (B, D) GL-Ad/RU-mIL-12 was administered by i.h injection 
(n=9). Treated and untreated animals with Mif were sacrificed 10 hours after induction 
(day 1) and day 10.  
 
Fig.3. Effect of IL-12 on endogenous gene expression. Plasmids pTonL2(T)-mIL-12 or 
Ealbα1AT- rtTA2S-M2 (carrying only the transactivator gene) were injected into 
BALB/c mice (n=3) and Dox was administered i.p during 3 days before sacrifice. Liver 
samples of both groups of animals were used for microarray analysis. (A) The 
normalized expression signal of 8 genes untreated (TAd, grey columns) or IL-12-treated 
animals (TAdIL, black columns) is represented: interferon gamma (Ifn-γ), interferon 
gamma inducible protein 47 (Ifi47), Ifi203, interferon activated gene 203 (Ifi203), 
interferon inducible GTPase 1 (Iigp1), interferon regulatory factor 8 (Irf8, also called 
Icsbp1), signal transducer and activator of transcription 1 (Stat1), interferon regulatory 
factor 1 (Irf1). Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) signal was 
included as a control reference gene that does not change. The normalized expression 
signal corresponds to the average of ratios of log2 expression signals. The standard 
error for the 3 samples is also indicated. In this way, a relative increment of 1.1 and 1.6 
(in the log2 ratio scale) corresponds to a 2.15 and 3.0 fold induction (in the lineal ratio 
scale), respectively. (B) Heatmap of the hierarchical cluster analysis of a set of the 94 
liver-specific gene-probesets selected. Indicated are the down- (green) and up- (red) 
regulated genes in samples where mIL12 was induced (TAdIL 1, 2 and 3) and the ones 
that were not (TAd 1, 2 and 3). Arrows points the probesets corresponding to relevant 
genes. (C-F) Differential expression of a subset of liver-specific genes (albumin, α-1 
antitrypsin, transthyretin and hemopexin) in mice (n=5) injected with pTonL2(T)-mIL-
 31
12 or pTonL2(T)-hIL-12 and treated for 8 days with Dox. Real time RT-PCR was 
performed to determine mRNA content in the liver. *significant differences (*P<0.05, 
**P<0.01). 
 
Fig.4. Effect of IL-12 on an IL-12 induced promoter. pTonL2(T)-hIL12 or pTonL2(T)-
mIL12 plasmids were co-injected with EalbPα1AT-hAAT (A) or EIIPHpx-hAAT (B) 
in C57BL/6J mice (n=5) followed by 8 consecutive days of induction with Dox in 
drinking water. In both cases concentration of hAAT was determined in serum at the 
indicated time point. EIIPHpx: enhancer II of the human hepatitis B virus fused to 
human hemopexin promoter. hAAT: human α1-antitrypsin reporter gene. 
 
Fig.5. Murine hepatocytes do not present a functional IL-12 receptor. The expression of 
IL-12 receptor β1 and β 2 chains (A, B), as well as IFN- γ receptor α and β chains (C, 
D) was analyzed by real time RT-PCR in livers or isolated hepatocytes from C57BL/6J 
mice, and the hepatocellular carcinoma cell line Hepa 1-6. 
 
Fig.6. Kinetics of IL-12 and IFN-γ expression in different immunodeficient mice. GL-
Ad/RU-mIL-12 (2x108 IU) was i.v. injected into wt C57BL/6J (n=5) mice, IFN-γ R-/- 
mice (n=6) or nod/SCID mice (n=3) followed by 8 consecutive days of treatment with 
Mif. Blood samples were collected 10 hours after the first and last inductions. (A) 
Serum levels of murine IL-12. (B) Serum levels of murine IFN-γ. 
 
Fig.7. Effect of NaB on the IL-12-mediated inhibition of gene expression. pTonL2(T)-
mIL12 was injected into BALB/c mice (n=5) followed by an 8 days-induction period 
with Dox, in the presence or absence of NaB at the indicated concentrations. (A) Levels 
 32
of IL-12 in serum. (B) Plasmid-derived and endogenous liver-specific gene expression 
determined by real time RT-PCR. The graphic represents the increase of mRNA content 
for each gene in animals treated with 2 g/kg NaB. (C) Stat-1 and Ifit2 mRNA levels in 
wt animals expressing IL-12 in the presence or absence of NaB. IFN-γ R-/- mice 
expressing IL-12 are included as negative control for IFN-γ pathway activation. 
*significant differences (P<0.05). ns: non-significant differences (P>0.05). 
Table 1. Primers used in this study 
Gene symbol 
GenBank 
accession Primer sequence 
Fragment 
Lenght (bp)
gapdh BC093508 s.5’-CCAAGGTCATCCATGACAAC-3’ 
as.5’-TGTCATACCAGGAAATGAGC-3’ 
464 
Alb1 NM_009654 s.5’-GCACACAAGAGTGAGATCGC-3’ 
as.5’-CAGCAGTCAGCCAGTTCACC-3’ 
269 
Ttr NM_013697 s.5’-GCTGGACTGGTATTTGTGTC-3’ 
as.5’-TGCAGCTCTCCAGACTC-3’ 
195 
Serpina1 S70316  s.5’-GCCTTCAGCCTATACCG-3’ 
as.5’-AGCACCCAGCTGGACAG-3’ 
620 
stat1 NM_009283 s.5’-GTGGTTCGAGCTTCAGCAGC-3’ 
as.5’-AGGTCATGGAAGCGGATGGT-3’ 
171 
Ifit2 NM_008332 s.5’-GGAGAGCAATCTGCGACAGC-3’ 
as.5’-CTGGATGAAGCCCTCAGCTT-3’ 
220 
Il12rb1 NM_008353 s.5’-CCATCATTTTCGCGTCTCTGGG-3’ 
as.5’-TACAACACCTCCGGGAAGTCCT-3’ 
202 
Il12rb2 NM_008354 s.5’-TGACAGCTGCTGGTGAAAGT-3’ 
as.5’-ATGTTGGAGGGTAAATAGCC-3’ 
601 
Ifngr1 NM_010511 s.5’-GATTCTGCTGGTGGTCCTGA-3’ 
as.5’-TCCAGGAACCCGAATACACC-3’ 
208 
Ifngr2 NM_008338  s.5’-TCCTCGCCAGACTCGTTTT-3’ 
as.5’-ATGTCCGTACAGTTCGGCTC-3’ 
191 
rtTA2s-M2  s.5’-GTCGGTATCGAAGGCCTGACG-3’ 
as.5’-ACAGGAACGCGAGCTGATTT-3’ 
304 
IRES  s.5’-GCCGTCTTTTGGCAATGTG-3’ 
as.5’-CCCCTAGGAATGCTCGTCAA-3’ 
75 
GLp65  s.5’-TGAACAGCGGATGAAAGAATCA-3’ 
as.5’-TTGACCTCATCTCCTCAAACTG-3’ 
185 
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